Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

NiTraSarc Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas - The NiTraSarc Phase II Trial

Trial Profile

NiTraSarc Combined Treatment With Nivolumab and Trabectedin in Patients With Metastatic or Inoperable Soft Tissue Sarcomas - The NiTraSarc Phase II Trial

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Trabectedin (Primary)
  • Indications Leiomyosarcoma; Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms NiTraSarc
  • Most Recent Events

    • 06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology.
    • 26 May 2023 According to PharmaMar media release, results from this study will be presented at the annual meeting of the American Society of Clinical26 May 2023 Oncology (ASCO), to be held on June 2-6, 2023, both virtually and in situ in Chicago, USA.
    • 07 Nov 2022 Status changed from active, no longer recruiting to completed.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top